- Home
- STTK vs FINW Comparison
STTK vs FINW Comparison
Compare STTK & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- FINW
- Stock Information
- Founded
- STTK 2016
- FINW 1999
- Country
- STTK United States
- FINW United States
- Employees
- STTK N/A
- FINW N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- FINW Commercial Banks
- Sector
- STTK Health Care
- FINW Finance
- Exchange
- STTK Nasdaq
- FINW Nasdaq
- Market Cap
- STTK 37.6M
- FINW 196.2M
- IPO Year
- STTK 2020
- FINW 2021
- Fundamental
- Price
- STTK $0.83
- FINW $15.73
- Analyst Decision
- STTK Hold
- FINW Buy
- Analyst Count
- STTK 4
- FINW 4
- Target Price
- STTK $3.00
- FINW $20.75
- AVG Volume (30 Days)
- STTK 410.6K
- FINW 76.7K
- Earning Date
- STTK 07-31-2025
- FINW 07-24-2025
- Dividend Yield
- STTK N/A
- FINW N/A
- EPS Growth
- STTK N/A
- FINW N/A
- EPS
- STTK N/A
- FINW 0.91
- Revenue
- STTK $4,606,000.00
- FINW $72,056,000.00
- Revenue This Year
- STTK N/A
- FINW $38.17
- Revenue Next Year
- STTK N/A
- FINW $18.44
- P/E Ratio
- STTK N/A
- FINW $17.58
- Revenue Growth
- STTK 69.65
- FINW 7.66
- 52 Week Low
- STTK $0.69
- FINW $10.29
- 52 Week High
- STTK $4.99
- FINW $20.94
- Technical
- Relative Strength Index (RSI)
- STTK 41.39
- FINW 71.92
- Support Level
- STTK $0.77
- FINW $15.23
- Resistance Level
- STTK $0.87
- FINW $14.37
- Average True Range (ATR)
- STTK 0.08
- FINW 0.56
- MACD
- STTK -0.02
- FINW 0.23
- Stochastic Oscillator
- STTK 17.65
- FINW 100.00
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.